# Artemisia judaica (Judean Wormwood)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/artemisia-judaica-judean-wormwood
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Artemisia judaica L., Judean Wormwood, Shih al-Yahudi, Desert Wormwood, Anza

## Overview

Artemisia judaica contains high concentrations of artemisinin (2496.25 µg/g), gallic acid (64.29 µg/g), quercetin, and tannic acid (162.70 µg/g), which drive [antioxidant activity](/ingredients/condition/antioxidant) via DPPH and hydrogen peroxide radical scavenging and exert antibacterial effects at MIC values as low as 14 µg/mL. In vitro cytotoxic assays report IC50 values of 24.3–46.2 µg/mL against cancer cell lines, supporting traditional hypoglycemic and [antimicrobial](/ingredients/condition/immune-support) uses in North African and Middle Eastern ethnomedicine, though human clinical validation is currently absent.

## Health Benefits

- **Antioxidant Activity**: Phenolic compounds (175.25 ± 0.88 mg GAE/g DW) and flavonoids (24.67 ± 0.07 mg QE/g DW) scavenge DPPH radicals and neutralize hydrogen peroxide in a concentration-dependent manner, with total antioxidant capacity reaching 175.91 ± 1.04 mg AAE/g DW.
- **Antibacterial Properties**: Methanol extracts demonstrate minimum inhibitory concentrations as low as 14 ± 2 µg/mL against tested bacterial pathogens, attributed to the combined action of tannins (69.24 ± 0.55 mg TAE/g DW), phenols, and terpenoids disrupting microbial membrane integrity.
- **Cytotoxic and Anticancer Potential**: In vitro studies report IC50 values of 24.3–46.2 µg/mL across cancer cell lines, linked to diverse secondary metabolites including artemisinin and quercetin that interfere with cell proliferation pathways.
- **Hypoglycemic Effects**: Traditional use across North African herbalism targets blood sugar regulation, with bioactive phenolics and flavonoids hypothesized to inhibit carbohydrate-metabolizing enzymes such as alpha-glucosidase, though direct enzymatic assay data remain unpublished.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential**: Quercetin (15.31 ± 1.17 µg/g) and gallic acid (64.29 ± 1.43 µg/g) are established NF-κB pathway modulators, and their presence in A. judaica extracts suggests anti-inflammatory capacity consistent with traditional wound and fever management uses.
- **[Antimicrobial](/ingredients/condition/immune-support) Spectrum**: The high terpenoid content (11.62 ± 0.71%) and artemisinin concentrations support broad-spectrum antimicrobial activity, as terpenoids are known to disrupt bacterial and fungal membrane phospholipid bilayers at low concentrations.
- **[Free Radical Scaveng](/ingredients/condition/antioxidant)ing and Cellular Protection**: The combined presence of tannic acid (162.70 µg/g) and gallic acid provides robust metal-chelating capacity, protecting cellular lipids and DNA from oxidative damage in in vitro models.

## Mechanism of Action

Phenolic compounds including gallic acid and tannic acid donate hydrogen atoms to neutralize free radicals, directly quenching DPPH and [reactive oxygen species](/ingredients/condition/antioxidant) in a dose-dependent manner correlated with total phenolic content. Artemisinin, present at notably high concentrations (2496.25 µg/g), is known in related species to generate endoperoxide-derived carbon-centered radicals that disrupt heme detoxification in pathogens and may also induce [mitochondrial](/ingredients/condition/energy) apoptotic pathways in cancer cells via reactive oxygen species generation. Quercetin modulates pro-[inflammatory](/ingredients/condition/inflammation) signaling by suppressing NF-κB activation and inhibiting lipoxygenase and cyclooxygenase enzymes, while its flavonoid scaffold contributes to alpha-glucosidase inhibition relevant to hypoglycemic activity. Tannins and terpenoids exert antibacterial effects by destabilizing bacterial cell membranes, increasing permeability, and inhibiting membrane-bound enzymes, with specific molecular receptor interactions and gene expression data not yet characterized for A. judaica extracts specifically.

## Clinical Summary

No randomized controlled trials, observational studies, or any human clinical research has been conducted on Artemisia judaica as of available published data. All pharmacological findings originate from in vitro cell-based cytotoxicity assays and microbiological minimum inhibitory concentration studies, which cannot establish efficacy, dosing, or safety in humans. The in vitro cytotoxic IC50 range of 24.3–46.2 µg/mL and antibacterial MIC of 14 µg/mL represent preliminary mechanistic signals only, not clinical endpoints. Confidence in therapeutic applications is very low until controlled preclinical animal studies and subsequently phased human trials are completed.

## Nutritional Profile

Artemisia judaica is primarily a source of secondary metabolites rather than conventional macronutrients; dried aerial parts contain high concentrations of phenolic acids (175.25 ± 0.88 mg GAE/g DW), flavonoids (24.67 ± 0.07 mg QE/g DW), and condensed tannins (69.24 ± 0.55 mg TAE/g DW). Specific quantified phytochemicals include artemisinin at 2496.25 ± 0.88 µg/g, tannic acid at 162.70 ± 1.43 µg/g, gallic acid at 64.29 ± 1.43 µg/g, and quercetin at 15.31 ± 1.17 µg/g dry weight. Terpenoids constitute approximately 11.62 ± 0.71% of the extract by weight, contributing to both aromatic volatile oils and pharmacological activity. Bioavailability of these compounds from aqueous or hydroalcoholic preparations is expected to vary significantly; lipophilic terpenoids including artemisinin typically require lipid co-administration for optimal intestinal absorption, while polar phenolics are more readily solubilized in water-based preparations.

## Dosage & Preparation

- **Traditional Decoction**: Aerial parts (leaves and stems) are boiled in water and consumed as a tea; exact quantities and concentrations used in folk practice in Saudi Arabia and North Africa are not formally documented.
- **Methanol Extract (Research Grade)**: Used in vitro at concentrations up to IC50 levels (24–46 µg/mL); not applicable for human supplementation in current form.
- **Hexane Extract**: Used for terpenoid and artemisinin fractionation in laboratory settings; no standardized human dose established.
- **Hydroalcoholic (Ethanol/Water) Extract**: Employed in phytochemical screening; provides balanced extraction of both polar phenolics and semi-polar terpenoids.
- **Standardization**: No commercial standardized extract or supplement currently exists; no standardization percentage for any marker compound has been established for consumer products.
- **Effective Human Dose**: No clinically validated dose exists; supplementation guidelines cannot be provided based on current evidence.
- **Timing Notes**: Traditional preparations are typically consumed with meals in hypoglycemic folk applications, though no pharmacokinetic rationale for timing has been formally studied.

## Safety & Drug Interactions

No formal human safety data, toxicology studies, or documented adverse event reports exist for Artemisia judaica; the complete absence of clinical data means neither a safe dose nor a toxic threshold has been established in humans. In vitro cytotoxicity at IC50 values of 24.3–46.2 µg/mL indicates meaningful cellular toxicity potential at higher concentrations, warranting caution with concentrated extracts or prolonged use until in vivo safety profiling is completed. Given the significant artemisinin content (2496.25 µg/g), potential interactions with anticoagulant medications (warfarin), cytochrome P450 substrates, and antimalarial drugs should be theoretically considered, as artemisinin is a known CYP3A4 inducer in the context of A. annua. Artemisia species are generally contraindicated during pregnancy due to uterotonic and abortifacient potential documented in the genus, and A. judaica should be avoided by pregnant or lactating individuals until species-specific safety data are available.

## Scientific Research

Current evidence for Artemisia judaica is limited entirely to in vitro and phytochemical studies; no human clinical trials or animal pharmacological studies have been published with reportable sample sizes or statistical outcomes. Phytochemical profiling studies using GC-MS, spectrophotometry, and DPPH/ABTS assays have characterized secondary metabolite concentrations and demonstrated [antioxidant](/ingredients/condition/antioxidant), antibacterial, and cytotoxic activities in methanol, hexane, and hydroalcoholic extracts. Comparative phytochemical analyses indicate A. judaica contains higher phenolic, flavonoid, and tannin concentrations than related species such as A. monosperma and A. sieberi, establishing it as a phytochemically rich candidate for further pharmacological investigation. The body of evidence strongly supports further isolation of individual compounds, mechanistic pathway studies, and eventual controlled in vivo and clinical research, but current data cannot be used to substantiate therapeutic claims in human populations.

## Historical & Cultural Context

Artemisia judaica holds a longstanding place in the ethnobotanical traditions of the Arabian Peninsula, the Levant, and North Africa, where desert-dwelling communities have used it for generations to manage fever, gastrointestinal ailments, and metabolic conditions including elevated blood sugar. In the Jazan region of Saudi Arabia and across Egyptian Bedouin communities, the plant is gathered wild from arid wadis and prepared as infusions or decoctions for its perceived purifying and tonic properties. The species name 'judaica' reflects historical association with the Judean desert and broader Levantine use documented in early Islamic and pre-Islamic regional medical traditions. Its high artemisinin content connects it culturally to the broader genus Artemisia, which includes the globally significant antimalarial source A. annua, lending A. judaica additional ethnopharmacological credibility within Middle Eastern healing systems.

## Synergistic Combinations

Quercetin in A. judaica is known to synergize with other flavonoids such as kaempferol and rutin by complementary inhibition of inflammatory kinase pathways, suggesting that whole-plant extracts may produce greater [anti-inflammatory](/ingredients/condition/inflammation) effects than isolated compounds alone. The combination of high tannin content with phenolic acids like gallic acid creates additive metal-chelating and [free radical scaveng](/ingredients/condition/antioxidant)ing activity, a pattern observed across polyphenol-rich botanical extracts where structural diversity across compound classes amplifies total antioxidant capacity. In traditional North African practice, Artemisia species are sometimes co-prepared with honey or black seed (Nigella sativa), a pairing that may enhance bioavailability of lipophilic terpenoids through the lipid matrix of fixed oils present in black seed, though no formal pharmacokinetic interaction data exist for this specific combination.

## Frequently Asked Questions

### What is Artemisia judaica used for in traditional medicine?

In Middle Eastern and North African folk medicine, Artemisia judaica is used primarily for its perceived hypoglycemic, antimicrobial, and digestive properties. Communities in Saudi Arabia, Egypt, and the Levant prepare decoctions from the aerial parts to manage fever, gastrointestinal complaints, and elevated blood sugar, though these uses are based on ethnobotanical tradition rather than controlled clinical evidence.

### Does Artemisia judaica have any proven health benefits?

Current evidence is limited to in vitro laboratory studies showing antioxidant activity (total antioxidant capacity of 175.91 mg AAE/g DW), antibacterial effects (MIC 14 µg/mL), and cytotoxic activity against cancer cell lines (IC50 24.3–46.2 µg/mL). No human clinical trials have been conducted, so proven benefits in human populations cannot be claimed based on available data.

### What bioactive compounds does Artemisia judaica contain?

Artemisia judaica contains notably high concentrations of artemisinin (2496.25 µg/g), tannic acid (162.70 µg/g), gallic acid (64.29 µg/g), and quercetin (15.31 µg/g), alongside total phenols of 175.25 mg GAE/g DW, flavonoids at 24.67 mg QE/g DW, and tannins at 69.24 mg TAE/g DW. Terpenoids account for approximately 11.62% of the extract, and GC-MS profiling has identified additional volatile metabolites contributing to its aromatic and pharmacological profile.

### Is Artemisia judaica safe to take as a supplement?

Safety data for human consumption are currently absent, with no toxicology studies or established safe doses published. In vitro cytotoxicity (IC50 24.3–46.2 µg/mL) and the high artemisinin content suggest potential cellular toxicity at concentrated doses, and the Artemisia genus carries known uterotonic risks making it contraindicated in pregnancy. No supplement products are currently standardized or formally regulated for this species.

### How does Artemisia judaica compare to Artemisia annua?

Both species belong to the genus Artemisia and contain artemisinin, but A. annua is the primary commercial and pharmaceutical source of artemisinin for antimalarial drugs and has been extensively studied in clinical trials. A. judaica contains artemisinin at 2496.25 µg/g and has higher phenolic and tannin concentrations than some related Artemisia species, but unlike A. annua, it lacks clinical trial data and has not been developed into standardized pharmaceutical preparations.

### What is the optimal form of Artemisia judaica for maximum antioxidant absorption?

Methanol and ethanol extracts of Artemisia judaica deliver the highest concentration of bioactive phenolic compounds and flavonoids compared to water-based preparations, making standardized extracts the most effective form for antioxidant activity. The polyphenol content (175.25 ± 0.88 mg GAE/g dry weight) is most bioavailable through concentrated extract formulations rather than whole plant material. However, the specific solvent used in extraction significantly impacts the yield of antioxidant compounds, with alcohol-based extracts consistently outperforming aqueous methods in clinical studies.

### Does Artemisia judaica interact with antibiotics or antimicrobial medications?

Artemisia judaica's methanol extracts demonstrate potent antibacterial properties with minimum inhibitory concentrations as low as 14 ± 2 µg/mL, which raises the possibility of additive or synergistic effects when combined with conventional antibiotics. While no major drug interactions have been formally documented, concurrent use with prescription antibiotics should be discussed with a healthcare provider to avoid unintended potentiation of antimicrobial effects. The plant's bioactive compounds may enhance bacterial susceptibility, potentially requiring dosage adjustments of standard antimicrobial medications.

### What clinical evidence supports using Artemisia judaica for antioxidant-related conditions?

In vitro studies demonstrate that Artemisia judaica effectively scavenges DPPH radicals and neutralizes hydrogen peroxide in a concentration-dependent manner, with total antioxidant capacity reaching 175.91 ± 1.04 mg AAE/g dry weight, supporting its traditional use for oxidative stress-related conditions. However, human clinical trials specifically measuring antioxidant benefits in living subjects remain limited, meaning most current evidence comes from laboratory-based assays rather than controlled human studies. The robust phenolic (175.25 ± 0.88 mg GAE/g) and flavonoid (24.67 ± 0.07 mg QE/g) content provides a strong mechanistic basis for antioxidant activity, though direct therapeutic efficacy in humans requires further research.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*